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Abstract Cytochrome P450 (CYP) 4Fs metabolize leukotriene
B4 and other in£ammatory mediators in the arachidonic acid
cascade. Here we show that lipopolysaccharide (LPS) treatment
suppresses CYP4F4 and up-regulates CYP4F5 mRNA expres-
sion in rat liver whereas renal CYP4Fs are essentially un-
changed. BaSO4 treatment, in contrast, increases both hepatic
and renal CYP4F expression levels. Thus, distinct regulatory
mechanisms in CYP4F expression might operate under di¡erent
in£ammatory prompts. To examine hepatic totipotency, primary
hepatocytes were treated with varying doses of LPS resulting in
decrease in all the CYP4F isoforms. Treatment of hepatocytes
with 5 ng/ml of interleukin-1L mimics the in vivo e¡ects of LPS
on CYP4F expression.
2 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
Key words: In£ammation; Leukotriene B4 g-hydroxylase;
Cytochrome P450 4F; Interleukin-1; Lipopolysaccharide;
Chlorpromazine metabolism
1. Introduction
Leukotrienes are potent eicosanoid lipid mediators derived
from phospholipase-released arachidonic acid that are in-
volved in numerous homeostatic biological functions and in-
£ammation. Leukotriene B4 (LTB4), initially identi¢ed as an
activator of granulocytes [1], exerts its actions by a cell-sur-
face G protein-coupled receptor named BLT1 [2]. LTB4 ini-
tiates and ampli¢es chemotaxis, cell stimulation and release of
granule products/superoxide anions, indicating that it is a key
component of in£ammatory immune response [3^5]. Very re-
cently, two lines of BLT1-null mice have been generated [6,7].
Neutrophils and macrophages of these mice lacked LTB4-
induced calcium mobilization and exhibited reduced accumu-
lation of eosinophils, neutrophils and macrophages. The
cytochrome P4504F (CYP4F) subfamily encodes LTB4 g-hy-
droxylases that metabolize LTB4 to biologically less active
metabolites [8]. Metabolism of LTB4 in human polymorpho-
nuclear leukocytes by CYP4F3 to the 20-hydroxy derivative
leads to a dramatic loss of both chemotactic and aggregation
activity by polymorphonuclear leukocytes [9,10]. Further,
20-OH-LTB4 is very unstable and is readily metabolized to
20-COOH-LTB4 [11].
Yeast-expressed human neutrophil LTB4 g-hydroxylase
(CYP4F3) has a Km for LTB4 of 0.64 WM [12], consistent
with the Km for LTB4 obtained using isolated human neutro-
phils [9]. The liver form of CYP4F3, which is generated by
alternative splicing [13], and another human CYP4F, CYP4F2
[14], are thought to be responsible for removal of LTB4 from
human liver, a major organ for in£ammatory mediator inac-
tivation. Apart from LTB4, CYP4Fs also metabolize arachi-
donic acid and its other derivatives such as prostaglandins,
lipoxins, and hydroxyeicosatetraenoic acids (HETEs) [12,14^
19]. More recently considerable interest with respect to
CYP4F function in the kidney has been generated. The ability
of arachidonic acid g-hydroxylation, and formation of a po-
tent vasoconstrictor 20-HETE, in human kidney [20] suggests
an important role for CYP4Fs in renal functions such as
regulation of salt^water balance and arterial blood pressure.
In rats, the CYP4F subfamily consists of four related genes,
CYP4F1, CYP4F4, CYP4F5 and CYP4F6 [21,22]. The heter-
ologously expressed rat CYP4Fs show similar substrate spe-
ci¢cities to the human isoforms [16,19]. We speculate that the
CYP4F family might be able to modulate the extent of in-
£ammation by control of the tissue levels of these important
in£ammatory mediators. One way to provide support for this
hypothesis is to test whether the expression of CYP4Fs
changes under in£ammatory conditions, since these changes
are required to adjust the levels of in£ammatory mediators.
Administration of bacterial lipopolysaccharide (LPS) has been
used extensively as a model of sepsis to study the regulation of
P450s during an in£ammatory response [23]. BaSO4, on the
other hand, is a particulate irritant that produces sterile peri-
tonitis and a¡ects the expression of several P450s. Many of
the e¡ects of LPS and BaSO4 on P450 expression are thought
to be mediated by cytokines like interleukin-1 (IL-1), IL-6,
tumor necrosis factor-K (TNF-K) and interferon-Q.
In this study, we ¢rst determined the distribution and con-
stitutive expression of CYP4F isoforms in both liver and kid-
ney. Second, we investigated the regulation of hepatic and
renal CYP4F gene expressions under in£ammatory conditions
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using LPS- and BaSO4-treated rat models. To delineate
whether the e¡ects of LPS were direct and/or indirect, primary
cultured rat hepatocytes were challenged with di¡erent doses
of LPS. The role of IL-1L in regulating CYP4Fs, a predom-
inant pro-in£ammatory cytokine released in the liver upon
LPS injection, was also tested. Finally, an e¡ort was made
to correlate changes in mRNA levels with changes in catalytic
activity using non-speci¢c and speci¢c substrates.
2. Materials and methods
2.1. Animal treatments
Six to eight week old male Fisher 344 rats (Harlan, Indianapolis,
IN, USA) were used. The animals were allowed free access to food
and water at all times. Chromatographically puri¢ed Escherichia coli
LPS, serotype 0127:B8 (Sigma Chemicals, St. Louis, MO, USA), was
dissolved in sterile saline to a ¢nal concentration of 1.0 mg/ml by
sonication and injected intraperitoneally at a dose of 1.0 mg/kg
body weight. BaSO4 was suspended in phosphate-bu¡ered saline
and injected intraperitoneally at a concentration of 5.0 g/kg body
weight. Control animals received an equivalent volume of sterile sa-
line. The animals were killed 24 h after treatments by CO2 asphyx-
iation. The livers and kidneys were removed for RNA or microsome
preparation. These procedures were approved by the Animal Care and
Use Committees of both Emory University and the University of
Texas Medical School at Houston.
2.2. Hepatocyte isolation, culture and treatments
Rat hepatocytes were isolated by in situ collagenase perfusion as
described previously [24]. The viability of hepatocyte preparations was
70^85% (trypan blue exclusion) and the yield was 200^400U106 viable
cells/liver. The hepatocytes were plated in Waymouth’s medium con-
taining 0.15 mM insulin on 60 mm culture dishes coated with 0.4 ml
Matrigel (2.0 mg/ml) at a density of 3.5U106 cells per dish. Medium
was changed to remove the dead cells 4 h after the plating and every
48 h thereafter. Hepatocytes were cultured for 5 days before beginning
treatments to allow for recovery of stable expression of P450s. They
were treated on day 5 by changing to medium containing speci¢c
concentrations of LPS (10 pg/ml^100 ng/ml), IL-1L (5 ng/ml) or ve-
hicle.
2.3. RNA and microsome preparations
Total RNA was prepared according to the method of Chomczynski
[25]. Microsomes were prepared as described by Saito and Strobel
[26]. All procedures were carried out at 4‡C. The excised livers were
washed and homogenized in bu¡er A (150 mM KCl, 10 mM EDTA,
0.5 mM phenylmethylsulfonyl £uoride (PMSF), 50 WM vitamin E, pH
7.5). The homogenate was centrifuged at 10 000Ug for 20 min. The
pellet was resuspended in bu¡er A and centrifuged at the same speed.
The supernatant fraction was further centrifuged at 105 000Ug for 60
min. The pellet was homogenized in half of the pellet volume of bu¡er
A, and centrifuged under the same conditions. The ¢nal pellet was
resuspended in bu¡er B (0.25 M sucrose, 10 mM EDTA, 1 mM
PMSF, 250 WM vitamin E, and 1 mM dithiothreitol, pH 7.5) and
stored at 380‡C for further analysis. The microsomal protein concen-
trations were determined using the bicinchoninic acid procedure [27].
2.4. Quantitative real time polymerase chain reaction (QRTPCR)
All samples were DNase-treated using RQ1 DNase (Promega,
Madison, WI, USA). The quality of the isolated RNA was assessed
by electrophoresis on 1% agarose gels based on the integrity of 28S
and 18S bands after ethidium bromide staining. PCR primers and
£uorescent probe sequences for CYP4F isoforms were designed as
described previously [28]. Aliquots (200 ng) of total RNA were reverse
transcribed in quadruplicate (including an RT blank to account for
ampli¢cation of contaminating genomic DNA). Ampli¢cation was
performed using an ABI Prism 7700 (Applied Biosystems, Norwalk,
CT, USA) at 95‡C for 1 min, followed by 40 cycles of 95‡C for 12 s
and 60‡C for 1 min. Standard curves were generated by plotting Ct
versus the log of the amount of amplicon (custom made by IDT,
Coralville, IA, USA) for speci¢c 4Fs (500 ag^5 pg), and were used
to compare the relative amount of a particular CYP4F mRNA in the
samples.
2.5. CYP4F immunoblotting
Microsomal protein samples were boiled in Laemmli bu¡er and
resolved on 4^15% Tris^glycine sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis gels. Proteins were transferred to nitrocellu-
lose membranes using a semi-dry transfer apparatus. Membranes were
blocked overnight with Superblock1 (Pierce, Rockford, IL, USA)
followed by 2 h incubation in 1:250 dilution of polyclonal primary
antibody against CYP4F5 (is speci¢c for 4Fs but does not distinguish
among the isoforms). Membranes were then washed and incubated at
room temperature with horseradish peroxidase (HRP)-conjugated sec-
ondary antibody (1:1000 dilution) for 1 h. Immunoreactivity was
detected using an HRP chemiluminescence system (Pierce). These ex-
periments were repeated three times each.
2.6. Chlorpromazine and LTB4 metabolism
Metabolism of chlorpromazine (CPZ) and LTB4 by liver micro-
somes was determined using high performance liquid chromatography
methods as previously described [16,29]. Brie£y, the reactions were
carried out at 37‡C for 20 min in the presence of appropriate bu¡er,
substrate and microsomal concentrations. The reaction products were
extracted with 3 ml of ethyl acetate, dried gently under N2 gas, resol-
ubilized in 100 Wl of mobile phase. These products were passed over a
cyano (for CPZ) or C18 (for LTB4) column and measured with a UV
detector set at 254 and 270 nm respectively. The quantities of newly
formed metabolites were determined from the peak area read from the
standard curves prepared for 20-OH-LTB4 (0.3^5 WM), CPZ-sulfoxide
and nor-CPZ (1^20 WM). The CYP4F activity inhibition was tested by
pre-incubating the microsomes with 10 WM 17-octadecynoic acid for
10 min at 37‡C.
2.7. Statistical analysis
Results are expressed as meanTS.E.M. from at least ¢ve indepen-
dent sets of experiments. Comparisons were made using Student’s
t-test and one-way analysis of variance with a post-hoc Tukey’s multi-
ple range test. Values of P6 0.05 were considered statistically di¡er-
ent.
3. Results
3.1. Constitutive expression and distribution of CYP4Fs in liver
and kidney
The expression of each CYP4F isoform in liver and kidney
was quanti¢ed using QRTPCR with isoform-speci¢c primers
and probes. The amount of each CYP4F isoform in the sam-
ple was calculated from the standard curve and normalized to
internal control r-cyclophilin. The data are expressed as per-
centage of total CYP4F expression in liver or in kidney. The
results show that CYP4F1 is the dominant isoform in both
liver and kidney, accounting for 71.6% and 95.1% of CYP4F
expression, respectively (Fig. 1a,b). In liver, CYP4F4 has the
second highest expression (18.5%), followed by CYP4F6
(9.8%). The expression of CYP4F5 is only 0.1% of total he-
patic CYP4F. In kidney, all other CYP4Fs accounted for only
5% of CYP4F expression, and CYP4F4 was barely detected
with this technique.
3.2. Regulation of CYP4F expression by LPS and BaSO4
The regulation of expression of hepatic and renal CYP4Fs
was evaluated at the mRNA level by QRTPCR. In liver
(Fig. 2a), LPS and BaSO4 did not change the expression of
CYP4F1 and 4F6, two major isoforms of CYP4Fs. LPS
showed opposite e¡ects on CYP4F4 and 4F5 causing a 50%
down-regulation of CYP4F4 and 60% up-regulation of
CYP4F5. On the other hand, BaSO4 led to a 40% increase
of CYP4F4 expression. In kidney (Fig. 2b), none of the
CYP4F isoforms were a¡ected by LPS treatment, however,
BaSO4 induced the expression of CYP4F1 and 4F6 two- to
three-fold over the control levels.
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3.3. E¡ect of LPS and BaSO4 treatment on CPZ metabolism
by liver microsomes
The metabolism of CPZ by CYP4F4 and CYP4F5 proteins
has been demonstrated by Boehme and Strobel [30], who
found nor-CPZ and CPZ-sulfoxide to be the major metabo-
lites. We examined whether LPS or BaSO4 administration in
vivo can a¡ect metabolism of this neuroleptic drug by rat liver
microsomes. The major metabolites produced by the micro-
somes were nor-CPZ and CPZ-sulfoxide, the same as seen
when puri¢ed CYP4F proteins were used. No hydroxy-CPZ,
N-oxide-CPZ or nor-CPZ-sulfoxide metabolites were pro-
duced (data not shown). The turnover rates were determined
from standard curves using pure nor-CPZ and CPZ-sulfoxide.
As shown in Table 1, both LPS and BaSO4 treatment caused
a signi¢cant decrease in turnover rate for nor-CPZ (58% and
54% respectively), and CPZ-sulfoxide (60% and 68% respec-
tively) formation.
3.4. E¡ect of LPS and BaSO4 on CYP4F-mediated LTB4
metabolism by liver microsomes
LTB4, a speci¢c substrate for CYP4Fs, was used as a probe
substrate to investigate the e¡ect of LPS and BaSO4 on
CYP4F activity in liver. The g-hydroxylase activity of
CYP4Fs was carried out by monitoring the production of
20-OH-LTB4 as described earlier [16]. The results showed
no signi¢cant di¡erence between controls and LPS-treated
animals while the BaSO4 treatment resulted in a 30% increase
in g-hydroxylase activity (see Table 1). The speci¢city of the
reaction was tested using the CYP4F-speci¢c inhibitor 17-oc-
tadecynoic acid, which resulted in up to 53% inhibition of
g-hydroxylase activity regardless of the treatment (data not
shown). Immunoblot analysis utilizing a polyclonal CYP4F5
antibody revealed a similar degree of CYP4F induction after
BaSO4 treatment while no change was apparent after LPS
challenge (see Fig. 3).
3.5. Suppression of CYP4F mRNA in hepatocytes treated with
LPS
The objective of this experiment was to de¢ne the in vitro
Fig. 1. QRTPCR analysis of CYP4F isoforms in rat liver and kid-
ney. Total RNA from rat liver or kidney (n=5) was prepared and
assayed using QRTPCR as described in Section 2. Each sample was
normalized to r-cyclophilin. The pie charts represent the relative dis-
tribution of CYP4F isoforms in (a) liver and (b) kidney.
Fig. 2. E¡ects of LPS and BaSO4 treatment on hepatic (a) and re-
nal (b) CYP4F isoforms. LPS (1.0 mg/kg) or BaSO4 (5.0 g/kg) was
injected intraperitoneally in rats (n=5) as described in Section 2.
Total RNA prepared from controls and treated animals was ana-
lyzed for individual CYP4F isoform expression by QRTPCR analy-
sis using r-cyclophilin as an internal standard. *P6 0.05 compared
to control.
Table 1
E¡ect of LPS and BaSO4 treatment on liver microsome turnover
rate for CPZ and LTB4 metabolism
Treatment Nor-CPZ CPZ-sulfoxide 20-OH-LTB4
Control 311.1T 5.5 3451T 313 27.18T 0.93
LPS 180.4T 4.2* 1855T 150* 26.32T 2.55
BaSO4 188T 2.5** 2359T 82.7* 34.23T 1.63*
CPZ or LTB4 metabolism was measured in vitro as described in
Section 2. Values (pmol formed/min/mg of protein) are the means
of determinations on three individual liver microsomal samples. The
statistical signi¢cance was determined by one-way analysis of var-
iance (*P6 0.05; **P6 0.01).
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e¡ects of varying doses of LPS on isolated rat hepatocytes
and determine whether LPS can act directly on hepatocytes
to a¡ect CYP4F expression. Many gene regulation studies
have been conducted using primary hepatocyte cultures. It is
known that in general P450 expression decreases drastically at
the beginning of the culture period, and recovers gradually.
The basal expression levels of CYP4F isoforms also decreased
after 24 h in culture. However, the expression levels recovered
and reached a plateau at day 3^5. Based on these observa-
tions, cells were cultured for 5 days before beginning any
treatments. As shown in Fig. 4a^d, 24 h treatment of hepa-
tocytes with LPS resulted in a signi¢cant decrease in mRNA
expression of all CYP4F isoforms. CYP4F1 showed the max-
imal decrease among the four isoforms with up to 80% sup-
pression observed even at the lowest dose (10 pg/ml) used. A
similar degree of suppression in CYP4F4, 4F5 and 4F6 ex-
pression was observed at a 100-fold higher dose of LPS. In-
terestingly, a mild increase in CYP4F4, 4F5 and 4F6 expres-
sion was noted at 10 ng when compared to 1 ng of LPS.
3.6. IL-1L treatment of hepatocytes mimics the in vivo e¡ects
of LPS on CYP4F expression
Treatment of hepatocytes with 5 ng/ml of IL-1 for 24 h
resulted in an isoform-speci¢c response by CYP4Fs (Fig. 5).
CYP4F1 expression increased by 29% while CYP4F4 expres-
sion dropped by 70% when compared to control. In this case,
CYP4F5 was the most responsive isoform and showed a 3.5-
fold induction upon IL-1 treatment. No signi¢cant changes in
CYP4F6 levels were observed after IL-1 treatment. Interest-
ingly, these data correlate very well with the hepatic CYP4F
response after LPS injection.
4. Discussion
Several studies have revealed that the CYP4F subfamily
metabolizes leukotriene and prostaglandin products of arachi-
donic acid cascades, which play a role in in£ammation and
blood vessel tone regulation. In this study, we used QRTPCR
to analyze CYP4F constitutive expression in liver and kidney,
attempting to correlate the distributions with their putative
roles in physiological and pathophysiological processes.
Fig. 3. Immunoblot analysis of CYP4F levels after LPS and BaSO4
treatments. Liver microsomes were prepared as described in Section
2. 50 Wg of microsomal proteins from each sample were separated
electrophoretically and then transferred on to nitrocellulose mem-
brane. Membranes were blotted and analyzed using CYP4F5 anti-
body.
Fig. 4. Concentration-dependent e¡ects of LPS treatment on CYP4F expression in primary hepatocytes. Rat hepatocytes were cultured on Ma-
trigel for 5 days and treated with di¡erent concentrations of LPS for 24 h. The expression of CYP4F isoforms was quantitated by QRTPCR
as described earlier. Each data point represents the meanTS.E.M. of ¢ve independent culture plates and is expressed as percent of control.
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CYP4F1 is the most highly expressed isoform in rat liver and
kidney whereas CYP4F5 shows a rather low constitutive ex-
pression. Kikuta et al. [17] demonstrated that puri¢ed
CYP4F1 is quite active as a hydroxylase towards LTB4, lip-
oxins, prostaglandins and HETEs. Such a high expression of
CYP4F1 implies it may contribute heavily to the endogenous
eicosanoid pool that a¡ects the delicate balance of hepatic and
renal physiological functions. This hypothesis is supported by
the evidence that besides LTB4 metabolism, CYP4F-depen-
dent conversion of arachidonic acid to 20-HETE, a potent
vasoconstrictor and activator of protein kinase C, may a¡ect
important renal functions such as hypertension and water^salt
balance [20,31,32]. On the other hand, in a recent report,
Bylund et al. [19] have demonstrated that CYP4F5 has a
much lower Km for LTB4 (9.7 WM for CYP4F5 vs. 26 WM
for CYP4F6), and is 30 times more e⁄cient than CYP4F6 in
metabolizing LTB4. The lower constitutive level but higher
catalytic e⁄ciency of CYP4F5 compared to other CYP4Fs
suggests that CYP4F5 might be an inducible CYP4F isoform
and its expression levels during an in£ammatory state might
be an important determinant of resolution status.
In order to test the role of various CYP4F isoforms in
in£ammation control, we studied the e¡ects of LPS and
BaSO4, two separate in£ammatory prompts, on CYP4F
gene expression. Administration of bacterial LPS has been
used extensively as a model of sepsis to study the regulation
of P450 genes during an in£ammatory response [23]. Similar
to LPS, BaSO4 can cause a systematic in£ammatory response
but they are di¡erent in some aspects. First, LPS injection can
directly activate Kup¡er cells and cause a high cytokine con-
centration in the liver as compared with rats which receive
BaSO4 injected intraperitoneally [33]. The cytokine response
pro¢les of the two models are also di¡erent. In addition, in-
jection of the particulate irritant is thought to initiate a sterile
peritonitis after phagocytosis of these particulates by macro-
phages [34] or by Kup¡er cells after the particulates enter the
blood circulation and are transported to the liver [35]. There-
fore the response to BaSO4 is completely macrophage- or
Kup¡er cell-dependent. In contrast, LPS may directly a¡ect
the expressions of some P450s in hepatocytes. Further, LPS
administration may induce the expression of nitric oxide syn-
thase, whereas particulate irritants do not [33,36]. Thus, the
mechanisms through which LPS and BaSO4 operate may be
di¡erent or may share certain mediators such as the cytokines
to a greater or lesser degree.
Our results show that CYP4Fs are regulated in a tissue-
speci¢c and isoform-speci¢c manner. In liver, CYP4F1 and
4F6 are not a¡ected by either treatment. The closely related
CYP4F4 and 4F5 behaved in an opposite fashion upon LPS
challenge. The major CYP4Fs in kidney, CYP4F1 and 4F6,
only respond to BaSO4. Using Northern blot analysis, we
previously reported that both CYP4F4 and 4F5 mRNA de-
crease in liver after LPS and BaSO4 treatments [24]. The dis-
crepancy in our results from these two studies is most likely a
result of lack of speci¢city and sensitivity of the Northern
probes used in the earlier study compared to the present
study. The QRTPCR technique used here is much more sen-
sitive than Northern analysis and provides a speci¢c and
better quantitation of individual CYP4F mRNA levels. This
discrepancy is clear when we look at relative amounts of
CYP4F5 (0.1%) vs. CYP4F4 (18.5%) in liver as determined
by QRTPCR. The CYP4F5 levels in liver are very low in
comparison to CYP4F1, 4F4 and 4F6 and therefore even a
low degree of cross-hybridization of CYP4F5 probe will ad-
versely a¡ect its quantitation compared to highly abundant
other CYP4Fs.
In order to de¢ne whether the changes in hepatic CYP4F
expression were direct or indirect e¡ects of LPS, cultured rat
hepatocytes were subjected to varying concentrations of LPS.
All four isoforms displayed a decrease upon LPS challenge
with a minor increase seen at a 10 ng dose for CYP4F4 and
4F5. The increase in CYP4F4 and 4F5 levels at higher doses
of LPS treatment seems unusual and needs further character-
ization. However, we speculate that higher doses of LPS may
produce additional regulatory mechanisms. The e¡ects of LPS
or BaSO4 on P450 mRNAs are known to be mimicked by
administration of interferon inducers and cytokines such as
IL-1, IL-6 and TNF-K, indicating that the suppression of
CYP gene products in LPS-induced in£ammation is likely
mediated by in£ammatory cytokines [37^39]. Also, cytokines
can act directly on hepatocytes to cause changes of CYP gene
expression. The mechanisms of this regulation are not known;
however, there is evidence that transcriptional events are
likely involved. For instance, Chen et al. [37], using a transi-
ently expressed reporter system, showed that CYP2C11 pro-
moter sequences are involved in the suppression of 2C11 by
IL-1 and IL-6.
We examined the role of IL-1L in regulating CYP4F ex-
pression since in response to LPS it is a major cytokine pro-
duced by Kup¡er cells and the resident macrophages of the
liver [23]. IL-1L selectively induced CYP4F1 and 4F5 expres-
sion while CYP4F4 expression was reduced. IL-1 has been
shown to mediate its pro-in£ammatory e¡ects through nuclear
factor-UB (NF-UB), a dimeric transcription factor formed by
the hetero- or homodimerization of proteins in the Rel family,
including p50 and p60 [40]. NF-UB plays a central role in
in£ammation through the regulation of genes encoding pro-
in£ammatory cytokines, adhesion molecules, chemokines,
growth factors, and inducible enzymes such as cyclooxyge-
nase-2 and inducible nitric oxide synthase [40]. CYP4F5 ge-
nomic characterization revealed there are several NF-UB bind-
ing sites in its promoter as well as a 5P £anking region [41].
Whether the other members in the CYP4F subfamily also
Fig. 5. E¡ects of IL-1L treatment on CYP4F expression in primary
hepatocytes. Hepatocytes were cultured as described in Fig. 3, and
treated with 5 ng/ml of IL-1L for 24 h. The expression of CYP4F
isoforms was quantitated by QRTPCR as described earlier. The
data represent the meanTS.E.M. of ¢ve independent culture plates
and are expressed as percent of control. *P6 0.05 compared to con-
trol.
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contain these sites and whether they are functional remains to
be seen.
Interestingly, the results obtained from hepatocyte treat-
ment with IL-1L are quite similar to the in vivo e¡ects of
LPS on hepatic CYP4Fs. This suggests that intraperitoneally
injected LPS may be causing increased production of cyto-
kines such as IL-1 which directly a¡ect CYP4F expression
in liver. On the other hand, dissimilarities in CYP4F regula-
tion by LPS in the in vivo and in vitro experiments might be
explained by the fact that the hepatocyte cultures used in this
study were essentially devoid of any macrophages or Kup¡er
cells. Therefore, the chances of cytokine-mediated CYP4F
regulation by LPS in this case remain low. In accordance
with this view is the study by Milosevic et al. [42] comparing
the responses of hepatocytes cocultured with Kup¡er cells
with those of hepatocytes alone, and showing that suppression
of CYP2B1 mRNA by LPS was mediated by TNF-K release
from the Kup¡er cells. The e¡ects of other pro- and anti-
in£ammatory cytokines on CYP4F expression are being ac-
tively pursued.
To determine whether changes of CYP4F mRNAs in rat
liver result in accompanying changes in enzyme activities, we
performed CPZ and LTB4 metabolism assays in liver micro-
somes from di¡erent treatment groups. CYP4F4 and 4F5
have been shown to be better catalysts for metabolism of
CPZ than CYP1A and 2B [29,30]. The major products of
CPZ metabolism by liver microsomes are nor-CPZ and
CPZ-sulfoxide, which are the same as the products produced
using puri¢ed CYP4F isoforms. According to our results, LPS
and BaSO4 treatment can suppress demethylation activity to
58% and 60%, respectively, and sulfoxidation activity to 54%
and 68%, respectively. In addition to the CYP4F subfamily,
activity towards CPZ in the liver microsomes might represent
contributions due to the 2C and 2D isoforms as well. Alter-
natively, when LTB4, a speci¢c substrate of the CYP4F sub-
family, was utilized, the results were completely correlative
with mRNA changes. For example, we did not observe any
change in LTB4 g-hydroxylation after LPS treatment, how-
ever, an up-regulation of CYP4F5 and down-regulation of
CYP4F4 mRNA was seen. We speculate that the opposite
regulation of CYP4F4 and 4F5 may cancel one another leav-
ing no net change in activity. On the other hand, BaSO4
treatment caused a 30% increase in LTB4 g-hydroxylation
which may be accounted for by the increased CYP4F4
mRNA expression observed upon BaSO4 challenge. Similar
results obtained after immunoblot analysis using a polyclonal
CYP4F antibody support the above hypothesis and augment
the need for isoform-speci¢c antibodies to distinguish each
CYP4F form at the protein level. The generation of such anti-
bodies is being actively pursued.
Although in£ammation is an integral part of the host de-
fense mechanism against a variety of pathogens as well as
tissue injury, it often produces a myriad of unwanted compli-
cations. LTB4 is a classical chemotactic agent which acts pri-
marily on the neutrophil to enhance its adherence to endothe-
lium [5]. Adherence of circulating neutrophils to the
microvascular endothelium is the initial step in diapedesis,
the process by which leukocytes migrate through blood vessels
to accumulate at sites of infection or injury [43]. The mecha-
nisms underlying neutrophil^endothelial cell interactions are
currently under intense investigation. The proximity of hepa-
tocytes to eicosanoid-producing endothelial cells and Kup¡er
cells prompted us to determine the expression and function of
LTB4 g-hydroxylases during in£ammatory conditions. Our
¢ndings provide evidence that in£ammatory triggers such as
LPS and BaSO4 can in£uence expression of enzymes which
are involved in LTB4 breakdown in an isoform- and tissue-
speci¢c manner possibly in attempting to re-establish homeo-
stasis. The precise physiological functions of individual
CYP4F isoforms remain unclear and deserve further investi-
gation.
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